The importance and future of antimicrobial surveillance studies

Clinical Infectious Diseases

Volumn 47, Issue SUPPL.1, 2008, Pages

  Masterton, Robert ^a  

^a AYR HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTIBUTEN; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; FOSFOMYCIN; GATIFLOXACIN; GENTAMICIN; GLYCOPEPTIDE; IMIPENEM; MACROLIDE; MIDECAMYCIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN; TRIMETHOPRIM; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; BACTERIUM; DRUG SURVEILLANCE PROGRAM; ENTEROBACTER CLOACAE; HAEMOPHILUS INFLUENZAE; HUMAN; KLEBSIELLA PNEUMONIAE; MORAXELLA CATARRHALIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; INCIDENCE; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE;

EID: 51549095871     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/590063     Document Type: Review

References (58)

1. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003; 31:481-98.
2. Jones RN. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Semin Respir Crit Care Med 2003; 24:121-34.
3. Bruinsma N, Kristinsson KG, Bronzwaer S, et al. Trends of penicillin and erythromycin resistance among invasive Streptococcus pneumoniae in Europe. J Antimicrob Chemother 2004; 54:1045-50.
4. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470-85.
5. DeRyke CA, Maglio D, Nicolau DP. Defining the need for new antimicrobials: clinical and economic implications of resistance in the hospitalised patient. Expert Opin Pharmacother 2005; 6:873-89.
6. Lieberman JM. Appropriate antibiotic use and why it is important: the challenges of bacterial resistance. Pediatr Infect Dis J 2003; 22:1143-51.
7. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006; 42(Suppl 2):S82-9.
8. Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999; 159:1127-32.
9. Kollef MH. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin Infect Dis 2008; 47(Suppl 1):S3-13 (in this supplement).
10. Mutnick AH, Rhomberg PR, Sader HS, Jones RN. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). J Antimicrob Chemother 2004; 53:290-6.
11. Palcevski G, Ahel V, Vlahovic-Palcevski V, Ratchina S, Rosovic-Bazijanac V, Averchenkova L. Antibiotic use profile at paediatric clinics in two transitional countries. Pharmacoepidemiol Drug Saf 2004; 13: 181-5.
12. Meyer E, Schwab F, Jonas D, Rueden H, Gastmeier P, Daschner FD. Surveillance of antimicrobial use and antimicrobial resistance in intensive care units (SARI): 1. Antimicrobial use in German intensive care units. Intensive Care Med 2004; 30:1089-96.
13. Bronzwaer SL, Cars O, Buchholz U, et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis 2002; 8:278-82.
14. Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Surveillance Report, data summary from January 1996 through December 1997: a report from the National Nosocomial Infections Surveillance (NNIS) System. Am J Infect Control 1999; 27:279-84.
15. Fridkin SK, Steward CD, Edwards JR, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 1999; 29:245-52.
16. Felmingham D, White AR, Jacobs MR, et al. The Alexander Project: the benefits from a decade of surveillance. J Antimicrob Chemother 2005; 56(Suppl 2):ii3-21.
17. Masterton RG. Surveillance studies: how can they help the management of infection? J Antimicrob Chemother 2000; 46(Suppl B):53-8.
18. Mertens R, Van Den Berg JM, Fabry J, Jepsen OB. HELICS: a European project to standardise the surveillance of hospital acquired infection, 1994-1995. Euro Surveill 1996; 1:28-30.
19. Suetens C, Savey A, Labeeuw J, Morales I, HELICS-ICU. The ICUHELICS programme: towards European surveillance of hospital-acquired infections in intensive care units. Euro Surveill 2002; 7:127-8.
20. Suetens C, Morales I, Savey A, et al. European surveillance of ICUacquired infections (HELICS-ICU): methods and main results. J Hosp Infect 2007; 65(Suppl 2):171-3.
21. Thornsberry C, Ogilvie P, Kahn J, Mauriz Y. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. Diagn Microbiol Infect Dis 1997; 29:249-57.
22. Thornsberry C, Sahm DF, Kelly LJ, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin Infect Dis 2002; 34(Suppl 1):S4-16.
23. Sahm DF. Resistance issues and community-acquired respiratory infections. Clin Cornerstone 2003; (Suppl 3):S4-11.
24. Stelling JM, Travers K, Jones RN, Turner PJ, O'Brien TF, Levy SB. Integrating Escherichia coli antimicrobial susceptibility data from multiple surveillance programs. Emerg Infect Dis 2005; 11:873-82.
25. Jones RN, Stilwell MG, Hogan PA, Sheehan DJ. Activity of linezolid against 3,251 strains of uncommonly isolated gram-positive organisms: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2007; 51:1491-3.
26. Jones RN, Mendes C, Turner PJ, Masterton R. An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004. Diagn Microbiol Infect Dis 2005; 53:247-56.
27. Turner PJ. Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. Diagn Microbiol Infect Dis 2008; 60:185-92.
28. Rhomberg PR, Deshpande LM, Kirby JT, Jones RN. Activity of meropenem as serine carbapenemases evolve in US medical centers: monitoring report from the MYSTIC Program (2006). Diagn Microbiol Infect Dis 2007; 59:425-32.
29. European Antimicrobial Resistance Surveillance System (EARSS). About EARSS. Available at: http://www.rivm.nl/earss/about. Accessed 25 October 2007.
30. Marchese A, Schito GC. Recent findings from multinational resistance surveys: are we 'PROTEKTed' from resistance? Int J Antimicrob Agents 2007; 29(Suppl 1):S2-5.
31. Farrell DJ, File TM, Jenkins SG. Prevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years (2000 to 2004) of the PROTEKT US study. J Clin Microbiol 2007; 45:290-3.
32. Kahlmeter G. The ECO7SENS Project: a prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens-interim report. J Antimicrob Chemother 2000; 46(Suppl A):15-22.
33. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO7SENS Project. J Antimicrob Chemother 2003; 51:69-76.
34. Kahlmeter G, Menday P. Cross-resistance and associated resistance in 2478 Escherichia coli isolates from the Pan-European ECO7SENS Project surveying the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections. J Antimicrob Chemother 2003; 52:128-31.
35. Meyer E, Jonas D, Schwab F, Rueden H, Gastmeier P, Daschner FD. Design of a surveillance system of antibiotic use and bacterial resistance in German intensive care units (SARI). Infection 2003; 31:208-15.
36. Meyer E, Schwab F, Gastmeier P, Rueden H, Daschner FD. Surveillance of antimicrobial use and antimicrobial resistance in German intensive care units (SARI): a summary of the data from 2001 through 2004. Infection 2006; 34:303-9.
37. Meyer E, Schwab F, Gastmeier P, Rueden H, Daschner FD, Jonas D. Stenotrophomonas maltophilia and antibiotic use in German intensive care units: data from Project SARI (Surveillance of Antimicrobial Use and Antimicrobial Resistance in German Intensive Care Units). J Hosp Infect 2006; 64:238-43.
38. Meyer E, Schwab F, Jonas D, Rueden H, Gastmeier P, Daschner FD. Temporal changes in bacterial resistance in German intensive care units, 2001-2003: data from the SARI (surveillance of antimicrobial use and antimicrobial resistance in intensive care units) project. J Hosp Infect 2005; 60:348-52.
39. Edwards JR, Peterson KD, Andrus ML, et al. National Healthcare Safety Network (NHSN) Report, data summary for 2006, issued June 2007. Am J Infect Control 2007; 35:290-301.
40. CDC. FAQ: CDC infection control in healthcare. Available at: http://www.cdc.gov/ncidod/dhqp/nhsn_FAQprotocols.html#G. Accessed 26 October 2007.
41. Biedenbach DJ, Toleman M, Walsh TR, Jones RN. Analysis of Salmonella spp. with resistance to extended-spectrum cephalosporins and fluoroquinolones isolated in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2004). Diagn Microbiol Infect Dis 2006; 54:13-21.
42. Masterton RG, Turner PJ. Trends in antimicrobial susceptibility in UK centres: the MYSTIC Programme (1997-2002). Int J Antimicrob Agents 2006; 27:69-72.
43. Nicolau DP. Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis 2008; 47(Suppl 1):S32-40 (in this supplement).
44. Goossens H, Grabein B. Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase- andAmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997-2004). Diagn Microbiol Infect Dis 2005; 53:257-64.
45. Bronzwaer SL, Goettsch W, Olsson-Liljequist B, Wale MC, Vatopoulos AC, Sprenger MJ. European Antimicrobial Resistance Surveillance System (EARSS): objectives and organisation. Euro Surveill 1999; 4:41-4.
46. Blahna MT, Zalewski CA, Reuer J, Kahlmeter G, Foxman B, Marrs CF. The role of horizontal gene transfer in the spread of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli in Europe and Canada. J Antimicrob Chemother 2006; 57:666-72.
47. Baquero F. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption? J Chemother 1999; 11: 35-43.
48. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289:885-8.
49. Baddour MM, Abuelkheir MM, Fatani AJ. Trends in antibiotic susceptibility patterns and epidemiology of MRSA isolates from several hospitals in Riyadh, Saudi Arabia. Ann Clin Microbiol Antimicrob 2006; 5:30.
50. Monnet DL, MacKenzie F, López-Lozano JM, et al. Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996-2000. Emerg Infect Dis 2004; 10:1432-41.
51. DeRyke CA, Lee SY, Kuti JL, Nicolau DP. Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance. Drugs 2006; 66:1-14.
52. Tam VH, Schilling AN, Neshat S, Poole K, Melnick DA, Coyle EA. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49:4920-7.
53. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42:521-7.
54. Guillemot D, Carbon C, Balkau B, et al. Low dosage and long treatment duration of β-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 1998; 279:365-70.
55. Masterton RG. Antibiotic cycling: more than it might seem? J Antimicrob Chemother 2005; 55:1-5.
56. Bonhoeffer S, Lipsitch M, Levin BR. Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci USA 1997; 94: 12106-11.
57. Marshall DA, McGeer A, Gough J, et al. Impact of antibiotic administrative restrictions on trends in antibiotic resistance. Can J Public Health 2006; 97:126-31.
58. Seppala H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997; 337:441-6.